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Capsid-like particles consisting of a hepatitis B core
(HBc) protein have been studied for their potential as
carriers for drug delivery systems (DDS). The hollow
HBc particle, which is formed by the self-assembly of
core proteins comprising 183 aa residues, has the abil-
ity to bind to various cells non-specifically via the
action of an arginine-rich domain. In this study, we
developed an engineered HBc particle that specifically
recognizes and targets human epidermal growth factor
receptor-related 2 (HER2)-expressing breast cancer
cells. To despoil the non-specific binding property of
an HBc particle, we genetically deleted the
C-terminal 150183 aa part of the core protein that
encodes the arginine-rich domain ("HBc). Then, we
genetically inserted a ZHER2 affibody molecule into
the 7881 aa position of the core protein to confer
the ability of target-cell-specific recognition. The con-
structed ZHER2-displaying HBc (ZHER2-"HBc) particle
specifically recognized HER2-expressing SKBR3 and
MCF-7 breast cancer cells. In addition, the ZHER2-
"HBc particle exhibited different binding amounts in
accordance with the HER2 expression levels of cancer
cells. These results show that the display of other types
of affibody molecules on HBc particles would be an
expandable strategy for targeting several kinds of
cancer cells that would help enable a pinpoint DDS.
Keywords: affibody/breast cancer cells/cell-specificity/
hepatitis B core/HER2.
Abbreviations: DDS, drug delivery system; FBS,
foetal bovine serum; HBc, hepatitis B core; HBV,
hepatitis B virus; HER2, human epidermal growth
factor receptor-related 2; HBc, HBc deletion mutant
lacking arginine-rich domain; SDSPAGE, sodium
dodecyl sulphatepolyacrylamide gel electrophoresis.
Anticancer drugs act against abnormal proteins in
cancer cells and present a large treatment effect.
However, they are often limited by their systemic toxi-
cities and side effects (1). Therefore, targeting ability is
an important factor for the development of drug de-
livery systems (DDS). To attain pinpoint delivery to
target cells, studies have extensively focused on fusing
targeting molecules with the drug itself (2) or on mod-
ifying the surface of the DDS carrier (3, 4). As the
targeting molecules, binding molecules such as antibo-
dies (5), peptides (6) and aptamers (7) are often used.
As a binding protein, the affibody is an attractive
molecule. An affibody is a small molecule that is
based on the Z-domain derived from Staphylococcus
aureus protein A (8). As a type of affibody, ZHER2
has the ability to bind to human epidermal growth
factor receptor-related 2 (HER2) that is a type 2 epi-
dermal growth factor receptor and is expressed on the
surface of breast cancer cells and ovarian cancer cells
(9, 10). Since natural ligands against HER2 have yet to
be found in nature (11), ZHER2 has been used as an
alternative molecular probe to diagnose (12) or target
HER2-expressing cells (13). In addition, various other
types of affibodies such as ZWT, Z440 and Z955 can be
used as the binding molecules to the Fc regions of
immunoglobulin G, insulin-like growth factor-1 recep-
tor and epidermal growth factor receptor, respectively
(8, 14, 15).
Hepatitis B virus (HBV) core (HBc) protein has been
studied for developing viral genome-free particles as
DDS carriers. The HBc is a 183-aa protein and
assembles spontaneously into icosahedral capsid-like
particles comprising 180240 subunits (16). The im-
portant feature of HBc is to transiently dissociate
and re-associate in the presence or absence of denatur-
ants, thereby enabling it to enclose molecules such as
drugs (17). In addition, the HBc can be produced in
large quantities, because it can be expressed in
Escherichia coli (18). The original HBc has been used
as a permeable particle because it has the ability to
bind to every cell (16), which is caused by an
arginine-rich domain (150183 aa) that recognizes
the cell surface heparan sulphate proteoglycan with
an electrostatic interaction (19). Additionally, foreign
molecules (e.g. green fluorescence protein) have been
successfully displayed on the surface of a HBc particle
without drastically altering its structure via insertion
into the 7881 aa position of the original HBc core
protein (20).
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HBc deletion mutant lacking arginine-rich domain
(HBc) consisting of the first 149 aa residues of a
core protein was developed as a deletion mutant lacking
a non-specific binding ability (21). TheHBc particle is
far more suitable for a DDS capsule than the original
HBc because of the particle’s capacity to incorporate
drugs (22) and the avoidance of host-derived RNA/
DNA-binding functions (21). However, despite the suc-
cessful development of the HBc particle, there have
been no reports of a binding-molecule-fused HBc.
In the present study, we developed a concept for
constructing a DDS carrier that is based on the
HBc particle and that can specifically recognize
target cancer cells. By genetically inserting a ZHER2
affibody between the 78 and 81 aa of a HBc core
protein, the engineered particle (ZHER2-HBc) specif-
ically bound to HER2-expressing breast cancer cells.
Materials and Methods
Construction of plasmids for the expression of core particles
The plasmids for expression of HBc, HBc and ZHER2-HBc were
constructed as described later. Fragments 1 and 2 encoding HBc
were amplified by polymerase chain reaction with the following pri-
mers: Fragment 1 (50-GGG GCT AGC AAT AAT TTT GTT TAA
CTT TAA GAA GGA GAT ATA CAT ATG ATG GAC ATT
GAC CCG TAT AA-30 and 50-ATT CTC TAG ACT CGA GAT
TAC TTC CCA CCC AGG TGG-30) and Fragment 2 (50-TAA TCT
CGA GTC TAG AGA ATT AGT AGT CAG CTA TGT-30 and 50-
CCC GTC GAC TTA GTG GTG GTG GTG GTG GTG ACA
TTG AGA TTC CCG AGA TT-30). Then, the whole-length frag-
ment encoding of HBc was amplified from Fragments 1 and 2 with
the following primers: (50-GGG GCT AGC AAT AAT TTT GTT
TAA CTT TAA GAA GGA GAT ATA CAT ATG ATG GAC
ATT GAC CCG TAT AA-30 and 50-CCC GTC GAC TTA GTG
GTG GTG GTG GTG GTG ACA TTG AGA TTC CCG AGA
TT-30). The amplified fragment was digested with NheI/SalI and
ligated into the XbaI/SalI sites of pET-22b (þ) (Novagen). The re-
sultant plasmid was designated as pET-22b-HBc. Fragment encod-
ing of HBc was amplified from pET-22b-HBc with the following
primers: (50-TAA TCT CGA GTC TAG AGA ATT AGT AGT
CAG CTA TGT-30 and 50-GGG GTC GAC AAG CTT TTA
GTG GTG GTG GTG GTG GTG AAC AAC AGT AGT TTC
CGG AA-30). The amplified fragment was digested with XbaI/SalI
and ligated into the same sites of pET-22b-HBc. The resultant plas-
mid was designated as pET-22b-HBc. A fragment encoding ZHER2
was amplified from pGLDsLd50-ZHER2 (23) with the following pri-
mers: (50-GGG CTC GAG GAC GGT GGT GGT GGT TCT GCG
CAA CAC GAT GAA GCC GT-30 and 50-GGG TCT AGA ACC
ACC ACC ACC TTT CGG CGC CTG AGC ATC AT-30). The
amplified fragment was digested with XhoI/XbaI and ligated into
the same sites of pET-22b-HBc. The resultant plasmid was desig-
nated as pET-22b-ZHER2-HBc.
Expression of core particles in E. coli
The plasmids for expression of HBc, HBc and ZHER2-HBc were
transformed into E. coli BL21. The culture of E. coli BL21 carrying
each plasmid was diluted with 1 l of fresh LB medium (1% tryptone,
0.5% yeast extract, 0.5% NaCl) in the presence of 100mg/ml ampi-
cillin and grown to OD600¼ 0.7 at 37C and a shaking speed
of 150 rpm. The culture was induced by adding isopropyl-b-
thiogalactopyranoside to a final concentration of 0.1 mM at 25C
overnight. Cells were then collected at 3,000 rpm and 4C for 15min.
Purification of core particles
To purify core particles fused with a His6-tag, we followed the pro-
cedure described by Wizemann and von Brunn (18) with minor
modifications. Briefly, the cell pellet was re-suspended in 50ml of
lysis buffer (pH 8.0) (50mM TrisHCl, 100mM NaCl, 5mM
EDTA, 0.2% Triton X-100, 10mM b-mercaptethanol). The cells
were lysed on ice by three cycles of sonication for 1min each with
2-min intervals to avoid heating of the material. The supernatant
was removed by centrifugation at 15,000 rpm and 4C for 30min.
The core particles in the pellet were washed in 50ml of lysis buffer
and collected by centrifugation at 12,000 rpm and 4C for 15min
twice. The pellet containing E. coli proteins was dissolved in 50ml
of dissociation buffer (pH 9.5) (4M urea, 200mM NaCl, 50mM
sodium carbonate, 10mM b-mercaptethanol) by overnight incuba-
tion in an ice-cold water bath. Then, the soluble fraction was sepa-
rated by centrifugation at 15,000 rpm and 4C for 20min.
Contaminating proteins were separated from the core particle
proteins using Ni2+-chelate affinity chromatography. A column
with 10ml of Ni2+-chelate agarose (Nacalai Tesque, Kyoto,
Japan) was pre-equilibrated with a 5-fold volume of dissociation
buffer. The prepared sample was loaded into a column and
washed with 30ml of dissociation buffer. Then, bound proteins
were eluted with 30ml of elution buffer (pH 9.5) (4M urea,
200mM NaCl, 50mM sodium carbonate, 10mM b-mercaptethanol,
1M imidazole). The eluate was fractionated in 1-ml aliquots. The
aliquots of each fraction were subjected to sodium dodecyl sul-
phatepolyacrylamide gel electrophoresis (SDSPAGE) and stained
with Coomassie brilliant blue to analyse their purity. The proteins of
purified fractions were polymerized to core particles by the removal
of the urea in a polymerization buffer (pH 7.0) (500mM NaCl,
50mM TrisHCl, 0.5mM EDTA).
SDSPAGE andwestern blotting
The expression of each core monomer was confirmed by western
blotting. The purified core particles were analysed by SDSPAGE
and electrotransferred onto a polyvinilidene fluoride membrane. For
the detection of the His6-tag, rabbit anti-6-His antibodies (Bethyl
Laboratories, Montgomery, TX, USA) were used as a primary anti-
body for immunoblotting, followed by anti-rabbit antibodies conju-
gated with alkaline phosphatase (Promega, Madison, WI, USA)
used as a second antibody. For the detection of Z protein, Goat
anti-protein A antibodies (Rockland Immunochemicals Inc.,
Gilbertsville, PA, USA) were used as the primary antibody for im-
munoblotting, followed by anti-goat antibodies conjugated with
alkaline phosphatase (Promega) used as the second antibody. The
membrane was stained with 5-bromo-4-chloro-3-indolyl phosphate
and nitro blue tetrazolium (Promega).
Atomic forcemicroscopy analysis of purified core particles
A gold chip (100-nm thickness of Au wafer; KST world, Fukui,
Japan) was covered with 200ml of solution containing core particles
at room temperature for 1 h. The gold chip was then washed with
10ml of polymerization buffer. After washing, the core particles
adsorbed onto the surface of the gold chip were measured using
an SPA400-Nanonavi atomic force microscopy unit (SII
Nanotechnology Inc., Chiba, Japan) with a cantilever
(BL-RC150VB-C1 from Olympus, Tokyo, Japan) at 0.8 kHz scan
speed according to the manufacturer’s procedure.
Dynamic light scattering analysis of purified core particles
The size of the purified core particles was determined by dynamic
light scattering using a Zetasizer Nano ZS (Malvern Instruments
Ltd, Worcestershire, UK), following the manufacturer’s procedure.
Cell culture
SKBR3 cells (human breast carcinoma) were maintained in RPMI
1640 medium supplemented with 10% (v/v) foetal bovine serum
(FBS) at 37C in 5% CO2. MCF-7 cells (human breast carcinoma)
and HeLa cells (human cervical carcinoma) were maintained in
Dulbecco’s modified Eagle medium supplemented with 10% FBS
at 37C in 5% CO2.
Flow cytometric evaluation
Purified core particles were reacted with Alexa Fluor 488
Succinimidyl Esters (Invitrogen Life Technologies, Carlsbad, CA,
USA) (2.6mol equiv) in phosphate-buffered saline for 1 h at room
temperature. The mixture then was dialysed against polymerization
buffer overnight to remove free Alexa Fluor 488. Approximately
2105 of SKBR3, MCF-7 and HeLa cells were seeded in individual
12-well plates. After washing with serum-free medium, indicated
volumes of Alexa Fluore 488-labelled core particles were added to
the medium, each of which was adjusted to a volume of 1ml, fol-
lowed by culturing of the cells for 1 h. After washing with serum-free
medium twice, the cells were incubated with FBS-containing medium
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for 2 h. Cells were suspended into a sheath solution and subjected to
a BD FACSCanto II flow cytometer equipped with a 488-nm blue
laser (BD Biosciences, San Jose, CA, USA). The green fluorescence
signal was collected through a 530/30-nm band-pass filter. The data
were analysed using the BD FACSDiva software v5.0 (BD
Biosciences).
Confocal laser scanningmicroscopy observation
Approximately 5104 of SKBR3, MCF-7 and HeLa cells were
seeded in individual 35-mm glass-bottom dishes. After washing
with serum-free medium, Alexa Fluore 488-labelled core particles
(10 mg/ml) were added and then cells were cultured for 1 h. After
washing with serum-free medium twice, the cells were incubated
with FBS-containing medium for 2 h. The cells were observed
using a LSM 5 PASCAL laser scanning confocal microscope (Carl
Zeiss, Oberkochen, Germany) equipped with a 63-fold oil immersion
objective lens with excitation by the 488-nm line of an argon laser
and emission collection by a 505-nm long-pass filter.
Results and Discussion
Expressionof coreproteins and formationof particles
As shown in Fig. 1, we first constructed the plasmid
to express the His6-tag-fused HBc, which consisted
of 183 aa residues of full-length core proteins. To elim-
inate the non-specific binding property of a core pro-
tein, we constructed the plasmid to express a HBc
consisting of 149 aa residues by deleting the corres-
ponding sequence to the C-terminal arginine-rich
domain (Fig. 1). Finally, we constructed the expression
plasmid for ZHER2-HBc, in which a ZHER2 affibody
molecule was inserted between the 78 and 81 aa
positions of the HBc (Fig. 1). As described in the
‘Materials and Methods’ section, we introduced these
plasmids into E. coli and produced each kind of HBc
particle.
First, to check the expression and purification of
each core protein, we performed western blot analysis
with anti-His6 antibody. Since three His6-specific
bands appeared at each desired position (HBc,
21 kDa; HBc, 17 kDa and ZHER2-HBc, 24 kDa),
successful expression and purification of the core pro-
teins were confirmed (Fig. 2, left). When using
anti-protein A antibody that can specifically bind to
the Z-derived affibodies, we detected the single band
only for ZHER2-HBc (24 kDa), as expected (Fig. 2,
right). Furthermore, secondary structural formation of
each core protein was confirmed by circular dichroism
spectra analysis (data not shown).
Second, to examine whether each core protein-
formed particle could be attributed to the capsid-like
structure, we analysed the purified core proteins by
dynamic light scattering (Fig. 3) and atomic force mi-
croscopy (Fig. 4). Two measurement analyses sug-
gested similar results, and it was strongly supported
that every core protein showed same particle-like struc-
ture that was 50 nm in diameter. According to previ-
ously reported for wild-type HBc particles analysis
(20, 21), it was assumed that the deletion of the
arginine-rich domain and the insertion of the ZHER2
affibody did not affect the self-assembly of the engin-
eered core proteins.
Fig. 1 Schematic representations of constructed core proteins (HBc, "HBc and ZHER2-"HBc). Wild-type HBc core protein consisted of an
assembly domain (grey prismatic body) and an arginine-rich domain (white prismatic body). For HBc core protein, the arginine-rich domain
(150183 aa) was deleted. For the ZHER2-HBc core protein, ZHER2 affibody (diagonal prismatic body) was inserted at the XhoI and XbaI sites
between 78 and 81 aa. For all constructs, His6-tag (black prismatic body) was fused to the C-termini.
24
21
17
(anti-His6 antibody)(anti-protein A antibody)
Fig. 2 Western blotting analyses of purified core particles. Purified
samples (HBc, HBc and ZHER2-HBc) were subjected to
SDSPAGE followed by immunoblotting using anti-His6 antibody
(for His6-tag, left image) and anti-protein A antibody (for ZHER2
affibody, right image).
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Examination of the ability of a ZHER2-DHBc particle
to recognize HER2-expressing breast cancer cells
Next, to evaluate the binding ability to HER2-
expressing breast cancer cells, we labelled the particles
with Alexa Fluor 488. Then, each kind of particle was
added to two types of HER2-positive human breast
cancer cells (SKBR3, expressing an abundant amount
of HER2, and MCF-7, expressing a tiny amount of
0
10
20
30
40
0.1 1 10 100 1000 10000
0
10
20
30
40
0.1 1 10 100 1000 10000
0
10
20
30
40
1 10 100 1000 10000
HBc
Δ HBc
ZHER2-ΔHBc
In
te
ns
ity
In
te
ns
ity
In
te
ns
ity
Diameter
Diameter
Diameter
0.1
A
C
B
Fig. 3 Particle size distribution analysis by dynamic light scattering. The average sizes of (A) HBc, (B) HBc and (C) ZHER2-HBc are
55.38 10.84 nm, 47.41 10.07 nm and 45.05 1.50 nm, respectively.
Fig. 4 AFM analyses of purified core particles. The macro and micro photographs show 2D and 3D images, respectively. HBc core particles were
analysed on the surface of the gold chip. (A) HBc, (B) HBc and (C) ZHER2-HBc. Scale bars, 50 mm.
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HER2) and a HER2-negative human cervical cancer
cell (HeLa) at several concentrations. After 3 h of in-
cubation, we measured the fluorescence intensity of
these cells by FACS.
As shown in Fig. 5A, the addition of a wild-type
HBc particle caused a dose-dependent increase in
fluorescence for all three kinds of cancer cells
(SKBR3, MCF-7 and HeLa), indicating that the ori-
ginal HBc particle binds to the cells in a non-specific
manner. The addition of a HBc particle did not ex-
hibit fluorescence for all three cells, supporting the
theory that the deletion of the arginine-rich domain
can cancel the non-specific binding ability of the ori-
ginal HBc (Fig. 5B). In contrast, the addition of a
ZHER2-HBc particle promoted an apparent fluores-
cence for SKBR3 cells in a dose-dependent manner
(white bars), whereas it never exhibited fluorescence
for the HeLa cells (black bars) (Fig. 5C).
Additionally, the addition of ZHER2-HBc to
MCF-7 showed a weaker fluorescence than in the
case of SKBR3 (Fig. 5C, grey bars). These results in-
dicate that ZHER2-HBc specifically recognized
HER2-expressing breast cancer cells and that the bind-
ing amount of ZHER2-HBc differed in accordance
with the HER2 expression levels in the cells.
Finally, to visually observe the binding ability of
these particles to the cells, Alexa Fluor 488-labelled
core particles were added into the cell cultures
(SKBR3, MCF-7 and HeLa) to give a final concentra-
tion of 10 mg/ml. After 3 h of incubation, the cells were
observed using a confocal laser scanning microscope
(Fig. 6). These results were consistent with the results
of the FACS analyses (Fig. 5), demonstrating that the
ZHER2-HBc particle has the ability to specifically
bind to HER2-expressing breast cancer cells.
In conclusion, we developed a HBc particle display-
ing a ZHER2 affibody that specifically recognizes
HER2-expressing breast cancer cells. It would be pos-
sible to incorporate drugs into ZHER2-HBc particles by
using the dissociation and association mechanism
regulated by salt concentration (24) or urea denaturant
(18), or by fusing peptidic drugs to C-terminal tail of
core protein (22). By inserting other types of affibody
Concentration of core particles [μg/ml]
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Fig. 5 Relative fluorescence units (RFUs) of HER2 positive
and negative cells treated with several concentrations of Alexa
Fluor 488-labelled HBc core particles. RFUs were determined
by FACS measurement. (A) HBc, (B) HBc and (C) ZHER2-HBc.
White bars, SKBR3 (HER2, þþþ); grey bars, MCF-7 (HER2, þ)
and black bars, HeLa (HER2, ).
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Fig. 6 Fluorescence images of SKBR3 (HER2, þþþ), MCF-7 (HER2, þ) and HeLa (HER2, ) treated with Alexa Fluor 488-labelled HBc core
particles (10 mg/ml). Cells were observed on a confocal laser scanning microscope. The fluorescence of Alexa Fluor 488 labeled HBc was shown in
white. Scale bars, 50 mm.
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molecules to the HBc, these engineered HBc core
particles could be used as pinpoint carriers to target
various kinds of cancer cells.
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